Ribonucleotide reductase inhibitors enhance cidofovir-induced apoptosis in EBV-positive nasopharyngeal carcinoma xenografts

International Journal of Cancer

Volumn 116, Issue 4, 2005, Pages 640-645

  Wakisaka, Naohiro ^a,b   Yoshizaki, Tomokazu ^b   Raab Traub, Nancy ^a,c   Pagano, Joseph S ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Cidofovir; Epstein Barr virus; Hydroxyurea; Ribonucleotide reductase inhibitor

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; CIDOFOVIR; HYDROXYUREA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXIDOREDUCTASE INHIBITOR; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LATENT VIRUS INFECTION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CYTOSINE; DRUG INTERACTIONS; ENZYME INHIBITORS; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; HYDROXAMIC ACIDS; HYDROXYUREA; MICE; MICE, NUDE; NASOPHARYNGEAL NEOPLASMS; PHOSPHONIC ACIDS; RIBONUCLEOTIDE REDUCTASES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 23244450268     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21096     Document Type: Article

References (49)

1. De Clercq E. In search of a selective antiviral chemotherapy. Clin Microbiol Rev 1997;10:674-93.
2. De Clercq E. Therapeutic potential of HPMPC as an antiviral drug. Rev Med Virol 1993;3:85-96.
3. Connelly MC, Robbins BL, Fridland A. Mechanism of uptake of the phosphonate analogue (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) in vero cells. Biochem Pharmacol 1993;46: 1053-7.
4. Cihlar T, Votruba I, Horska K, Liboska R, Rosenberg I, Holy A. Metabolism of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (HPMPC) in human embryonic lung cells. Collect Czech Chem Commun 1992;57:661-72.
5. Ho HT, Woods L, Bronson JJ, De Boeck H, Martin JC, Hitchcock MJM. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy-2- (phosphonylmethoxy)propyl] cytosine. Mol Pharmacol 1992;41:197-202.
6. Hitchcock MJM, Jaffe HS, Martin JC, Stagg RJ. Cidofovir, a new agent with potent anti-herpesvirus activity. Antiviral Chem Chemother 1996;7:115-27.
7. Xiong XF, Smith JL, Chen MS. The consequence of incorporation of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine by human cytomegalovirus DNA polymerase on DNA elongation. Antiviral Res 1995;26:A321.
8. Van Cutsem E, Snoeck R, Van Ranst M, Fiten P, Opdenakker G, Geboes K, Janssens J, Rutgeerts P, Vantrappen G, De Clercq E. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. J Med Virol 1995;45:230-5.
9. Snoeck R, Wellens W, Desloovere C, Van Ranst M, De Clercq E, Feenstra L. Treatment of severe recurrent laryngeal papillomatosis by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine (cidofovir). Antiviral Res 1996;30:A25.
10. Andrei G, Snoeck R, Piette J, Delvenne P, De Clercq E. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice. Oncol Res 1998; 10:533-9.
11. Nocentini G. Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy. Crit Rev Oncol Hematol 1996;22:89-126.
12. Huting DJ, Dresler SL. Dependence of UV-induced DNA excision repair on deoxyribonucleoside triphosphate concentrations of repair by hydroxyurea. Carcinogenesis 1985;6:1525-8.
13. Navarra P, Preziosi P. Hydroxyurea: new insights on an old drug. Crit Rev Oncol Hematol 1999;29:249-55.
14. Donehower RC. An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19:11-9.
15. Pagano JS, Blaser M, Buendia MA, Khalili K, Raab-Traub N, Roizman B. Infectious agents as causes of human cancer. Semin Cancer Biol 2004;48:1900-3.
16. Neyts J, Sadler R, De Clercq E, Raab-Traub N, Pagano JS. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl) cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice. Cancer Res 1998;58:384-8.
17. Murono S, Raab-Traub N, Pagano JS. Prevention and inhibition of nasopharyngeal carcinoma growth by antiviral phosphonated nucleoside analogs. Cancer Res 2001;61:7875-7.
18. Neyts J, De Clercq E. Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs. Antimicrob Agent Chemother 1999;43:2885-92.
19. Takimoto T, Kamide M, Umeda R. Establishment of Epstein-Barr virus (EBV)-associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch Otolaryngol 1984;239:87-92.
20. Murono S, Yoshizaki T, Sato H, Takeshita H, Furukawa M, Pagano JS. Aspirin inhibits tumor cell invasiveness induced by Epstein-Barr virus latent membrane protein 1 through suppression of matrix metalloproteinase-9 expression. Cancer Res 2000;60:2555-61.
21. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly (ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53:3976-85.
22. Soldani S, Scovassi AI. Poly (ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002;7:321-8.
23. Decker P, Isenberg D, Muller S. Inhibition of caspase-3-mediated poly (ADP-ribose) polymerase (PARP) apoptotic cleavage by human PARP autoantibodies and effect on cells undergoing apoptosis. J Biol Chem 2000;275:9043-6.
24. Raab-Traub N, Flynn K, Pearson G, Huang A, Levine P, Lanier A, Pagano JS. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int J Cancer 1987;39:25-9.
25. Pagano JS. Epstein-Barr virus. In: Jeffries DJ, De Clercq E, eds. Antiviral chemotherapy. New York: John Wiley and Sons, 1995. 155-95.
26. Busson P, Ganem G, Flores P, Mugtieret F, Clausse B, Caillou B, Brahan K, Wakasugi H, Lipinski M, Tursz T. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 1988;42:599-606.
27. Neyts J, De Clercq E. Mechanism of action of acyclic nucleoside phosphonates against herpes virus replication. Biochem Pharmacol 1994;47:39-41.
28. Xiong X, Smith JL, Kim C, Huang E, Chen MS. Kinetic analysis of the interaction of cidofovir diphosphate with human cytomegarovirus DNA polymerase. Biochem Pharmacol 1996;51:1563-7.
29. Lin JC, De Clercq E, Pagano JS. Inhibitory effects of acyclic nucleoside phosphonate analogs, including (S)-1(-3 hydroxyphosphonylmethoxypropyl) cytosine, on Epstein-Barr virus replication. Antimicrob Agents Chemother 1991;35:2440-3.
30. De Clercq E, Andrei G, Balzarini J, Hatse S, Liekens S, Naesens L, Neyts J, Snoeck R. Antitumor potential of acyclic nucleoside phosphonates. Nucleosides Nucleotides 1999;18:759-71.
31. Liekens S, Neyts J, De Clercq E, Verbeken E, Ribatti D, Presta M. Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res 2001;61:5057-64.
32. Liekens S, Verbeken E, De Clercq E, Neyts J. Potent inhibition of hemangiosarcoma development in mice by cidofovir. Int J Cancer 2001;92:161-7.
33. Bianchi V, Pontis E, Reichard P. Changes of deoxyribonucleotide triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. J Biol Chem 1986;261:16037-42.
34. van't Riet B, Wampler GL, Elford HL. Synthesis of hydroxy and amino substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. J Med Chem 1979;22:589-92.
35. Tihan T, Elford HL, Cory JG. Studies on the mechanism of inhibition of L1210 cell growth by 3, 4-dihydroxybenzohydroxamic acid and 3,4- dihydroxybenzamidoxime. Adv Enz Regul 1991;31:71-83.
36. Elford HL, van't Riet B, Wampler GL, Lin AL, Elford RM. Regulation of ribonucleotide reductase in mammalian cells by chemotherapeutic agents. Adv Enz Regul 1981;19:151-68.
37. Grusch M, Fritzer-Szekeres M, Fuhrmann G, Rosenberger G, Luxbacher C, Elford HL, Smid K, Peters GJ, Szekeres T, Krupitza G. Activation of caspases and inhibition of apoptosis by novel nucleotide reductase inhibitors amidox and didox. Exp Hematol 2001;29:623-32.
38. Abdulkarim B, Sabri S, Zelenika D, Deutsch E, Frascogna V, Klijanienko J, Vainchencker W, Joab I, Bourhis J. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene 2003;22: 2260-71.
39. Chodosh J, Holder VP, Can Y, Belgaumi A, Sample J, Sixbey JW. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998;177:1194-201.
40. Slobod KS, Taylor GH, Sandlund JT, Furth P, Helton KJ, Sixbey JW. Epstein-Barr virus-targetted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000;356:1493-4.
41. Pakakasama S, Eames GM, Morriss MC, Huls MH, Rooney CM, Heslop HE, Krance RA. Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Transplantation 2004;78:755-7.
42. Huyghe P, Dassonnville L, Fenaux P, Bailly C. Hydroxyurea-induced apoptosis in an EBV-immortalized lymphoblastoid cell line. Oncol Res 2004;14:235-45.
43. Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998; 55:1551-6.
44. Palmer S, Shafer RW, Merigan TC. Hydroxyurea enhances the activities of didanosine, 9-[2-(phosphonylmethoxy)ethyl] adenine, and 9-[2-(phosphonylmethoxy) propyl] adenine against drug-susceptible and drug-resistant human immunodeficiency virus isolates. Antimicrob Agents Chemother 1999;43:2046-50.
45. Lori F, Lisziewcz J. Rationale for the use of hydroxyurea as an anti-human immunodefifiency virus drug. Clin Infect Dis 2000;30:5193-7.
46. Tomita K, Plager JE. In vivo cell cycle synchronization of the murine sarcoma 180 tumor following altering periods of hydroxyurea blockade and release. Cancer Res 1979;39:4407-12.
47. Hatse S, Schols D, De Clercq E, Balzarini J. 9-(2-phosphonylmethoxyethyl) adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase. Cell Growth Differ 1999;10:435-46.
48. Huschtscha LI, Bartier WA, Ross CE, Tattesall MH. Characteristic of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996;73:54-60.
49. Voskaridou E, Kalotychou V, Loukopoulos D. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/β-thalassaemia. Br J Haematol 1995;89:479-84.